GSK’s Jemperli approved for treatment of endometrial cancer

August 1, 2023
Research and Development FDA, GSK, Jemperli, Oncology, dostarlimab, endometrial cancer

GSK has announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and …

Research shows neonatal stem cells could be used as treatment for Crohn’s disease

July 31, 2023
Research and Development Crohn’s disease, Gastrointestinal tract, Stem cells, gastrointestinal

Recent studies from the Ann & Robert H Lurie Children’s Hospital in Chicago have discovered that human neonatal cardiac-derived mesenchymal …

FDA approves a second OTC naloxone nasal spray

July 31, 2023
Medical Communications FDA, Nasal Spray, OTC, OTC Products, naloxone, opioids

The US Food and Drug Administration (FDA) has announced that it has approved RiVive, 3mg naloxone hydrochloride nasal spray for …

money_pills_2

Biogen to acquire Reata Pharmaceuticals

July 31, 2023
Business Services Biogen, Neurology, Reata Pharmaceuticals, acquisition

Biogen and Reata Pharmaceuticals have announced that they have entered a definitive agreement under which Biogen will acquire Reata for …

pills_spill

Eli Lilly shares data from two phase 3 tirzepatide studies

July 28, 2023
Research and Development Eli Lilly, Obesity, clinical trial, tirzepatide, weight loss

Eli Lilly has announced results from its two phase 3 tirezepatide studies in adult patients with obesity or who are …

genes

AstraZeneca’s Alexion partners with Pfizer for rare disease therapies

July 28, 2023
Research and Development Alexion, AstraZeneca, Pfizer, Rare Diseases, genomics, rare disease

Alexion, AstraZeneca’s Rare Disease division, has announced that it has entered a definitive purchase and licence agreement with Pfizer. The …

lungs

Hummingbird Bioscience initiates phase 1b trials for sqNSCLC

July 27, 2023
Research and Development Hummingbird Bioscience, Omico, Oncology, clinical trials, sqNSCLC

Hummingbird Bioscience has announced the initiation of two phase 1b clinical trials taking place in Australia. The trials will evaluate …

American Heart Association awards $2.1m to research link between migraine, strokes and CVD

July 27, 2023
Research and Development American Heart Association, Cardiology, cvd, migraine, stroke

The American Heart Association has announced that it will fund seven new scientific research studies to learn more about the …

medications-money-cure-tablets

Amarin gains positive opinion from Spanish Drug Pricing Committee for national reimbursement of Vazkepa in Spain

July 26, 2023
Sales and Marketing Amarin, Cardiology, Spanish Drug Pricing Committee, Vazkepa, cardiovascular

Amarin has announced that the Spanish Drug Pricing Committee has recommended the national reimbursement of Vazkepa (icosapent ethyl) in Spain …

Pharma pill manufacturing

Biovian announces investment in manufacturing facility in Finland

July 26, 2023
Manufacturing and Production Biovian, Pharmacy, facility, manufacturing

Biopharmaceutical based contract development and manufacturing organisation (CDMO) Biovian OY has announced an investment of over €50m to expand its …

pills-384846_960_720

AbbVie announces first patient dosed in phase 3 trial of upadacitinib in hidradenitis suppurativa

July 25, 2023
Research and Development AbbVie, Dermatology, HS, Rinvoq, clinical trial, upadacitinib

AbbVie has announced that the first patient has been dosed in its phase 3 Step-Up trial assessing Rinvoq (upadacitinib) for …

vaccinessssssssssssssssssss_1

Bavarian Nordic announces RSV vaccine did not meet all primary endpoints in phase 3 trial

July 25, 2023
Medical Communications Bavarian Nordic, Infections and infestations, RSV, Vaccine, clinical trial

Bavarian Nordic has announced that its phase 3 clinical trial of MVA-BN, its respiratory syncytial virus (RSV) vaccine candidate for …

Vaccine image

ViiV Healthcare gains positive CHMP opinion for cabotegravir for HIV prevention

July 24, 2023
Medical Communications CHMP, EMA, HIV, HIV/AIDS, ViiV Healthcare, cabotegravir

GSK has announced that ViiV Healthcare has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal …

Alnylam and Roche partner for RNAi therapeutic for treatment of hypertension

July 24, 2023
Research and Development Alnylam, Cardiology, Roche, hypertension, rnai, zilebesiran

Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the development and commercialisation of zilebesiran, …

stethoscope_and_background_doctor

Aevice Health gains FDA clearance for respiratory monitoring platform

July 21, 2023
Research and Development Aevice Health, Devices, FDA, respiratory monitoring

Remote respiratory monitoring solutions company Aevice Health has announced that it has received clearance from the US Food and Drug …

BioIVT acquires PrecisionMed for neurology and oncology research

July 21, 2023
Sales and Marketing Neurology, Oncology, neurology, oncology

BioIVT has announced that it has acquired PrecisionMed, a leading supplier of high-quality human biological material for genetics, drug discovery …

WHO releases Medical Product Alert for contaminated cough syrup

July 20, 2023
Medical Communications Pharmacy, WHO, cough syrups, medical product alert, world health organization

The World Health Organization (WHO) has shared a Medical Product Alert for an additional contaminated cough syrup medicine identified in …

Vaccine image

Pfizer shares new data from phase 2 trial for GBS maternal vaccine candidate

July 20, 2023
Research and Development Immunology, Pfizer, Vaccine, clinical trial

Pfizer has announced new data from its phase 2 study which assessed its hexavalent capsular polysaccharide (CPS) conjugate Group B …

Santhera closes exclusive license agreement with Catalyst Pharmaceuticals for Vamorolone

July 19, 2023
Medical Communications License Agreement, Musculo-skeletal disorder, Vamorolone, catalyst, santhera

Santhera Pharmaceuticals has announced the closing of its exclusive North American license agreement for vamorolone with Catalyst Pharmaceuticals. The agreement …

Renibus Therapeutics announces $47m financing for phase 3 trial

July 19, 2023
Business Services Cardiology, Financing, Renibus Therapeutics, clinical trial

Clinical stage biopharmaceutical company Renibus Therapeutics has announced that it has raised $47m from the initial closing of its Series …

The Gateway to Local Adoption Series

Latest content